PRIMARY PERITONEAL UNDIFFERENTIATED CARCINOMA
Clinical trials for PRIMARY PERITONEAL UNDIFFERENTIATED CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new PRIMARY PERITONEAL UNDIFFERENTIATED CARCINOMA trials appear
Sign up with your email to follow new studies for PRIMARY PERITONEAL UNDIFFERENTIATED CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo aims to outsmart Drug-Resistant ovarian cancer
Disease control OngoingThis early-phase trial tests a new drug (peposertib) combined with standard chemotherapy (PLD) in people with ovarian or related cancers that no longer respond to platinum-based treatment. The main goal is to find the safest dose and check for side effects. About 54 participants …
Matched conditions: PRIMARY PERITONEAL UNDIFFERENTIATED CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 04, 2026 16:18 UTC
-
New hope for recurrent ovarian cancer: drug combo extends life?
Disease control OngoingThis study looked at whether adding the drug bevacizumab to standard chemotherapy after surgery helps people with ovarian, peritoneal, or fallopian tube cancer that has come back live longer. Over 1,000 participants were randomly assigned to receive chemo alone or chemo plus beva…
Matched conditions: PRIMARY PERITONEAL UNDIFFERENTIATED CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 26, 2026 19:35 UTC